Know Cancer

or
forgot password

KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor


N/A
N/A
N/A
Open (Enrolling)
Both
Acute Myelogenous Leukemia

Thank you

Trial Information

KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor


Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR
donor.


Inclusion Criteria:



- Patient with acute myeloid leukemia (AML) undergoing screening for potential URD HCT

- Potential URD undergoing screening to provide a HCT graft to a patient with acute
myeloid leukemia (AML) at a participating institution

- Provides written consent

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Incidence of Relapse

Outcome Description:

To measure the impact of donor selection for KIR genotype in allogeneic URD HCT for AML on cumulative incidence of relapse. We will determine a quantitative estimate of the likelihood of better KIR donors identified with routine, non-directed donor selection along with KIR genotyping data. The observed incidence of success in a better KIR donor identified within 8 weeks will be compared to the original donor genotype expected frequencies identified in our retrospective genotyping of 1086 donors selected for AML transplants.

Outcome Time Frame:

2 Years

Safety Issue:

No

Principal Investigator

Daniel Weisdorf, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Masonic Cancer Center, University of Minnesota

Authority:

United States: Institutional Review Board

Study ID:

2010LSUC043

NCT ID:

NCT01288222

Start Date:

March 2011

Completion Date:

August 2014

Related Keywords:

  • Acute Myelogenous Leukemia
  • acute myelogenous leukemia
  • hematopoietic cell transplantation
  • unrelated donor
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location
Roswell Park Cancer Institute Buffalo, New York  14263
Fred Hutchinson Cancer Research Center Seattle, Washington  98109
Mayo Clinic Cancer Center Rochester, Minnesota  55905
Washington University School of Medicine Saint Louis, Missouri  63110
Hackensack University Medical Center Hackensack, New Jersey  07601
University of Pennsylvania Philadelphia, Pennsylvania  19104
Emory University Atlanta, Georgia  30322
Cleveland Clinic Cleveland, Ohio  44195
M.D. Anderson Cancer Center Houston, Texas  77030
Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota  55455
Indiana University Simon Cancer Center Indianapolis, Indiana  46202
Baylor Sammons Cancer Center Dallas, Texas  75246
Mayo Clinic - Scottsdale Scottsdale, Arizona  85259
Colorado Blood Cancer Institute Denver, Colorado  80218
Ohio State University Comprehensive Cancer Center Columbus, Ohio  
Kansas University Cancer Center Kansas City, Kansas  66160
New York Presbyterian Weill Cornell Medical Center New York, New York  10021
University of Chicago Medical Center Cancer Center Chicago, Illinois  60637
Methodist Healthcare System of San Antonio San Antonio, Texas  78229